Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

European Stakeholder Learnings Regarding Biosimilars: Part II—Improving Biosimilar Use in Clinical Practice
Liese Barbier, Steven Simoens, Arnold G. Vulto, et al.
BioDrugs (2020) Vol. 34, Iss. 6, pp. 797-808
Open Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Informing Patients about Biosimilar Medicines: The Role of European Patient Associations
Yannick Vandenplas, Steven Simoens, Philippe Van Wilder, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 2, pp. 117-117
Open Access | Times Cited: 55
European Stakeholder Learnings Regarding Biosimilars: Part I—Improving Biosimilar Understanding and Adoption
Liese Barbier, Steven Simoens, Arnold G. Vulto, et al.
BioDrugs (2020) Vol. 34, Iss. 6, pp. 783-796
Open Access | Times Cited: 53
Regulatory Information and Guidance on Biosimilars and Their Use Across Europe: A Call for Strengthened One Voice Messaging
Liese Barbier, Allary Mbuaki, Steven Simoens, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 27
Off-Patent Biologicals and Biosimilars Tendering in Europe—A Proposal towards More Sustainable Practices
Liese Barbier, Steven Simoens, Caroline Soontjens, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 6, pp. 499-499
Open Access | Times Cited: 29
Efforts of the Pharmaceuticals and Medical Devices Agency of Japanese regulatory agency in supporting biosimilar development and disseminate information
Ryosuke Kuribayashi, Aya Hariu, Yuka Saino, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome
Jun Ho Jang, Bing Han, Jinah Jung, et al.
BioDrugs (2025)
Open Access
Drawing on collective action theory to foster sustainable biosimilar markets – insights from co-creation workshops with UK and Belgian stakeholders
Teresa Barcina Lacosta, Arnold G. Vulto, Florian Turk, et al.
Expert Opinion on Biological Therapy (2025)
Closed Access
ASCO Policy Statement on Biosimilar and Interchangeable Products in Oncology
Gladys Rodriguez, Joan Mancuso, Gary H. Lyman, et al.
JCO Oncology Practice (2023) Vol. 19, Iss. 7, pp. 411-419
Open Access | Times Cited: 10
Barriers and Enablers Affecting the Uptake of Biosimilar Medicines Viewed Through the Lens of Actor Network Theory: A Systematic Review
C. Rieger, Judith Dean, Lisa Hall, et al.
BioDrugs (2024) Vol. 38, Iss. 4, pp. 541-555
Open Access | Times Cited: 3
“Biosimilar, so it looks alike, but what does it mean?” A qualitative study of Danish patients' perceptions of biosimilars
Meera Varma, Anna Birna Almarsdóttir, Louise C. Druedahl
Basic & Clinical Pharmacology & Toxicology (2022) Vol. 130, Iss. 5, pp. 581-591
Open Access | Times Cited: 14
How to balance valuable innovation with affordable access to medicines in Belgium?
Steven Simoens, Khadidja Abdallah, Liese Barbier, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 14
Biosimilars Versus Originators in Children With Juvenile Idiopathic Arthritis: A Real-World Experience
Maria Francesca Gicchino, Giusy Capasso, Alessia Amodio, et al.
Journal of Pediatric Health Care (2024) Vol. 39, Iss. 1, pp. 88-92
Closed Access | Times Cited: 2
Barriers to Biosimilar Prescribing Incentives in the Context of Clinical Governance in Spain
Félix Lobo, Isabel Río-Álvarez
Pharmaceuticals (2021) Vol. 14, Iss. 3, pp. 283-283
Open Access | Times Cited: 16
Biosimilars and interchangeable biosimilars: facts every prescriber, payor, and patient should know. Insulins perspective
Shashank Joshi, Shivani Mittra, Praveen Raj, et al.
Expert Opinion on Biological Therapy (2022) Vol. 23, Iss. 8, pp. 693-704
Open Access | Times Cited: 12
Interchangeability of Biosimilars: Overcoming the Final Hurdles
Liese Barbier, Arnold G. Vulto
Drugs (2021) Vol. 81, Iss. 16, pp. 1897-1903
Open Access | Times Cited: 15
Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians
Liese Barbier, Yannick Vandenplas, Steven Simoens, et al.
Journal of Pharmaceutical Policy and Practice (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 13
Pharmacists’ Perspectives of Biosimilars: A Systematic Review
Noraisyah Mohd Sani, Zoriah Aziz, Rema Panickar, et al.
BioDrugs (2022) Vol. 36, Iss. 4, pp. 489-508
Closed Access | Times Cited: 9
The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis
Yannick Vandenplas, Steven Simoens, Philippe Van Wilder, et al.
Health Research Policy and Systems (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 5
The economics of biosimilars and challenges to biosimilar adoption in low- and middle-income countries
Matthias Calamia, Ivo Abraham
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 8, pp. 653-657
Closed Access | Times Cited: 5
Awareness and Knowledge of Pharmacists toward Biosimilar Medicines: A Survey in Jordan
Muna Oqal, Bushra Hijazi, Abdelrahim Alqudah, et al.
International Journal of Clinical Practice (2022) Vol. 2022, pp. 1-10
Open Access | Times Cited: 8
Maximizing the benefits of using biosimilars in Egypt
Ahmad Nader Fasseeh, Baher Elezbawy, Kareem Ahmed El-Fass, et al.
Journal of Pharmaceutical Policy and Practice (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 4
Can Endangered Biosimilar Markets be Rescued? The Need to Bridge Competing Interests for Long-Term Gain
Teresa Barcina Lacosta, Arnold G. Vulto, Florian Turk, et al.
BioDrugs (2024) Vol. 38, Iss. 3, pp. 325-329
Closed Access | Times Cited: 1
Biosimilar SB17 versus reference ustekinumab in moderate to severe plaque psoriasis after switching: phase 3 study results up to week 52
Steven R. Feldman, Joanna Narbutt, Giampiero Girolomoni, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 1
Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking
Liese Barbier, Steven Simoens, Paul Declerck, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 7
Budget Impact Analysis of the Introduction of a Trastuzumab Biosimilar for HER2-Positive Breast Cancer in China
Qingqing Chai, Haini Wen, Yitian Lang, et al.
Clinical Drug Investigation (2022) Vol. 42, Iss. 11, pp. 937-947
Closed Access | Times Cited: 6
Page 1 - Next Page

Scroll to top